These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29396609)

  • 21. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting adenosine A2A receptors in Parkinson's disease.
    Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
    Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
    Kulisevsky J; Poyurovsky M
    Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
    Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
    Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
    Jenner P
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of Adenosine A
    Zheng J; Zhang X; Zhen X
    ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.
    Jones N; Bleickardt C; Mullins D; Parker E; Hodgson R
    Brain Res Bull; 2013 Sep; 98():163-9. PubMed ID: 23838432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
    Jenner P
    Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.
    Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
    Pharmacol Rev; 2013 Jan; 65(1):171-222. PubMed ID: 23319549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain α7 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients.
    Morissette M; Morin N; Grégoire L; Rajput A; Rajput AH; Di Paolo T
    Biochem Pharmacol; 2016 Jun; 109():62-69. PubMed ID: 27038656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists.
    Mori A; Shindou T
    Neurology; 2003 Dec; 61(11 Suppl 6):S44-8. PubMed ID: 14663009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
    Picconi B; Calabresi P
    Mov Disord; 2014 May; 29(6):715-9. PubMed ID: 24591264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia.
    Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C
    Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine A2A antagonists in Parkinson's disease: what's next?
    Hickey P; Stacy M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):376-85. PubMed ID: 22585137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.
    Pinna A
    CNS Drugs; 2014 May; 28(5):455-74. PubMed ID: 24687255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.